Skip Navigation

Close and don't show again.

Your browser is out of date.

You may not get the full experience here on National Journal.

Please upgrade your browser to any of the following supported browsers:

Early Tests Bode Well for Bioterrorism Treatment Early Tests Bode Well for Bioterrorism Treatment

NEXT :
This ad will end in seconds
 
Close X

Want access to this content? Learn More »

Forget Your Password?

Don't have an account? Register »

Reveal Navigation
 

 

Early Tests Bode Well for Bioterrorism Treatment

A potential drug for use against Marburg virus has been shown in initial testing to be safe for humans, the Boston Business Journal reported on Monday.

Pharmaceutical firm Sarepta Therapeutics announced that when the treatment was given in various dosage amounts over two weeks to 40 volunteers in a Phase 1 study, the drug was discerned to be generally safe, even at the largest dosage level.

 

Marburg virus is a hemorrhagic fever that can cause death in as many as nine out of 10 infected people. Given its lethality, the virus is a leading biological-terrorism concern.

Sarepta Therapeutics is developing its Marburg drug under a Defense Department contract. Additional work on the medication -- known as AVI-7288 -- depends on Pentagon approval.

This article was published in Global Security Newswire, which is produced independently by National Journal Group under contract with the Nuclear Threat Initiative. NTI is a nonprofit, nonpartisan group working to reduce global threats from nuclear, biological, and chemical weapons.

Don't Miss Today's Top Stories

Keeps me informed about national leadership concerns."

Senior Military Officer

The best!"

Mark, Compensation Analyst

Timely and informative."

Dave, HR specialist

I can browse over breakfast or while on the metro."

AJ, US Army Officer

Sign up form for the newsletter
Comments
comments powered by Disqus
 
MORE NATIONAL JOURNAL